QQQ   332.57 (-0.15%)
AAPL   173.02 (-0.10%)
MSFT   293.03 (-0.15%)
META   179.37 (-0.84%)
GOOGL   121.80 (-0.23%)
AMZN   144.16 (+0.68%)
TSLA   927.44 (-0.06%)
NVDA   188.81 (-0.79%)
NIO   20.81 (-2.30%)
BABA   92.79 (-1.50%)
AMD   99.87 (-1.13%)
MU   64.16 (-0.83%)
T   18.67 (+1.52%)
CGC   3.64 (-4.71%)
F   16.46 (+0.86%)
GE   80.14 (+0.41%)
DIS   125.30 (+0.84%)
AMC   24.15 (-0.25%)
PYPL   102.43 (+0.91%)
PFE   49.62 (-0.26%)
NFLX   246.99 (-0.85%)
QQQ   332.57 (-0.15%)
AAPL   173.02 (-0.10%)
MSFT   293.03 (-0.15%)
META   179.37 (-0.84%)
GOOGL   121.80 (-0.23%)
AMZN   144.16 (+0.68%)
TSLA   927.44 (-0.06%)
NVDA   188.81 (-0.79%)
NIO   20.81 (-2.30%)
BABA   92.79 (-1.50%)
AMD   99.87 (-1.13%)
MU   64.16 (-0.83%)
T   18.67 (+1.52%)
CGC   3.64 (-4.71%)
F   16.46 (+0.86%)
GE   80.14 (+0.41%)
DIS   125.30 (+0.84%)
AMC   24.15 (-0.25%)
PYPL   102.43 (+0.91%)
PFE   49.62 (-0.26%)
NFLX   246.99 (-0.85%)
QQQ   332.57 (-0.15%)
AAPL   173.02 (-0.10%)
MSFT   293.03 (-0.15%)
META   179.37 (-0.84%)
GOOGL   121.80 (-0.23%)
AMZN   144.16 (+0.68%)
TSLA   927.44 (-0.06%)
NVDA   188.81 (-0.79%)
NIO   20.81 (-2.30%)
BABA   92.79 (-1.50%)
AMD   99.87 (-1.13%)
MU   64.16 (-0.83%)
T   18.67 (+1.52%)
CGC   3.64 (-4.71%)
F   16.46 (+0.86%)
GE   80.14 (+0.41%)
DIS   125.30 (+0.84%)
AMC   24.15 (-0.25%)
PYPL   102.43 (+0.91%)
PFE   49.62 (-0.26%)
NFLX   246.99 (-0.85%)
QQQ   332.57 (-0.15%)
AAPL   173.02 (-0.10%)
MSFT   293.03 (-0.15%)
META   179.37 (-0.84%)
GOOGL   121.80 (-0.23%)
AMZN   144.16 (+0.68%)
TSLA   927.44 (-0.06%)
NVDA   188.81 (-0.79%)
NIO   20.81 (-2.30%)
BABA   92.79 (-1.50%)
AMD   99.87 (-1.13%)
MU   64.16 (-0.83%)
T   18.67 (+1.52%)
CGC   3.64 (-4.71%)
F   16.46 (+0.86%)
GE   80.14 (+0.41%)
DIS   125.30 (+0.84%)
AMC   24.15 (-0.25%)
PYPL   102.43 (+0.91%)
PFE   49.62 (-0.26%)
NFLX   246.99 (-0.85%)
NASDAQ:CDLX

Cardlytics - CDLX Stock Forecast, Price & News

$16.95
+0.19 (+1.13%)
(As of 08/16/2022 11:52 AM ET)
Add
Compare
Today's Range
$16.43
$17.22
50-Day Range
$12.36
$28.98
52-Week Range
$11.95
$99.47
Volume
10,354 shs
Average Volume
844,615 shs
Market Capitalization
$557.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.40

Cardlytics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
23.6% Upside
$20.40 Price Target
Short Interest
Bearish
17.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
1.20mentions of Cardlytics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$288,786 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.95) to ($2.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Business Services Sector

140th out of 339 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

27th out of 66 stocks

CDLX stock logo

About Cardlytics (NASDAQ:CDLX) Stock

Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.

Cardlytics Price Performance

CDLX Stock traded up $0.10 during mid-day trading on Tuesday, hitting $16.86. The company had a trading volume of 10,231 shares, compared to its average volume of 844,615. The company has a 50-day moving average price of $19.26 and a 200 day moving average price of $37.70. Cardlytics has a 12-month low of $11.95 and a 12-month high of $99.47. The company has a market capitalization of $554.53 million, a price-to-earnings ratio of -3.68 and a beta of 2.10. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.40.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Cardlytics from $47.00 to $35.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 29th. Needham & Company LLC cut their price objective on shares of Cardlytics from $24.00 to $19.00 and set a "buy" rating on the stock in a research report on Wednesday, August 3rd. Wells Fargo & Company decreased their target price on shares of Cardlytics from $15.00 to $14.00 and set an "equal weight" rating for the company in a report on Wednesday, August 3rd. Bank of America cut shares of Cardlytics from a "neutral" rating to an "underperform" rating and set a $14.00 price target on the stock. in a report on Tuesday, July 12th. Finally, Craig Hallum cut shares of Cardlytics from a "buy" rating to a "hold" rating and lowered their target price for the company from $50.00 to $20.00 in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $20.40.

Insider Activity at Cardlytics

In other Cardlytics news, Director Scott D. Grimes sold 9,257 shares of the stock in a transaction on Friday, August 5th. The stock was sold at an average price of $15.19, for a total value of $140,613.83. Following the sale, the director now owns 238,594 shares in the company, valued at $3,624,242.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Cardlytics news, Director Scott D. Grimes sold 9,257 shares of the company's stock in a transaction on Friday, August 5th. The stock was sold at an average price of $15.19, for a total transaction of $140,613.83. Following the completion of the sale, the director now owns 238,594 shares in the company, valued at $3,624,242.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Lynne Marie Laube sold 6,612 shares of the company's stock in a transaction on Friday, August 5th. The stock was sold at an average price of $15.19, for a total value of $100,436.28. Following the transaction, the chief executive officer now directly owns 306,271 shares in the company, valued at $4,652,256.49. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 10,000 shares of company stock worth $220,940 and have sold 18,458 shares worth $288,786. 3.70% of the stock is currently owned by insiders.

Receive CDLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

CDLX Stock News Headlines

Cardlytics, Inc. (NASDAQ:CDLX) CEO Sells $100,436.28 in Stock
Cardlytics (NASDAQ:CDLX) Price Target Cut to $14.00
Cardlytics: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive CDLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

CDLX Company Calendar

Last Earnings
5/04/2021
Today
8/16/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Computer programming, data processing, & other computer related
Sub-Industry
N/A
Current Symbol
NASDAQ:CDLX
Fax
N/A
Employees
591
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.40
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+20.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-128,570,000.00
Pretax Margin
-53.26%

Debt

Sales & Book Value

Annual Sales
$267.12 million
Book Value
$20.76 per share

Miscellaneous

Free Float
31,677,000
Market Cap
$557.49 million
Optionable
Not Optionable
Beta
2.10














CDLX Stock - Frequently Asked Questions

Should I buy or sell Cardlytics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CDLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDLX, but not buy additional shares or sell existing shares.
View CDLX analyst ratings
or view top-rated stocks.

What is Cardlytics' stock price forecast for 2022?

5 equities research analysts have issued twelve-month price targets for Cardlytics' stock. Their CDLX share price forecasts range from $14.00 to $35.00. On average, they predict the company's share price to reach $20.40 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for CDLX
or view top-rated stocks among Wall Street analysts.

How have CDLX shares performed in 2022?

Cardlytics' stock was trading at $66.09 at the beginning of the year. Since then, CDLX stock has decreased by 74.6% and is now trading at $16.76.
View the best growth stocks for 2022 here
.

When is Cardlytics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our CDLX earnings forecast
.

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) issued its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.22. The firm earned $53 million during the quarter, compared to the consensus estimate of $51.96 million. Cardlytics had a negative net margin of 50.15% and a negative trailing twelve-month return on equity of 15.46%. The company's revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.26) earnings per share.
Read the conference call transcript
.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $74.50 million-$76.50 million, compared to the consensus revenue estimate of $76.99 million.

What is Lynne Laube's approval rating as Cardlytics' CEO?

26 employees have rated Cardlytics Chief Executive Officer Lynne Laube on Glassdoor.com. Lynne Laube has an approval rating of 86% among the company's employees. 61.0% of employees surveyed would recommend working at Cardlytics to a friend.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Block (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.47%), JS Capital Management LLC (2.45%), Jennison Associates LLC (2.16%), State Street Corp (2.01%), Assenagon Asset Management S.A. (1.13%) and Northern Trust Corp (0.93%). Insiders that own company stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, S Aimee Lapic, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends
.

How do I buy shares of Cardlytics?

Shares of CDLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $16.76.

How much money does Cardlytics make?

Cardlytics (NASDAQ:CDLX) has a market capitalization of $551.24 million and generates $267.12 million in revenue each year. The company earns $-128,570,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Cardlytics have?

The company employs 591 workers across the globe.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The official website for the company is www.cardlytics.com. The company can be reached via phone at (888) 798-5802 or via email at ir@cardlytics.com.

This page (NASDAQ:CDLX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.